Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Ependymoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Glioblastoma (234)

Astrocytoma (74)

Oligodendroglioma (34)

Glioblastoma (234)

Astrocytoma (74)

Oligodendroglioma (34)

›

No biomarker	Ependymoma	No biomarker	Ependymoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Ependymoma	No biomarker	Ependymoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
No biomarker	Ependymoma	No biomarker	Ependymoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Ependymoma	No biomarker	Ependymoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
No biomarker	Ependymoma	No biomarker	Ependymoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Ependymoma	No biomarker	Ependymoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
CDK4 overexpression	Ependymoma	CDK4 overexpression	Ependymoma	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D
CCND1 overexpression	Ependymoma	CCND1 overexpression	Ependymoma	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D